Literature DB >> 8401913

Effects of beraprost on the transmembrane potentials of guinea-pig ventricular muscles during normoxia and hypoxia-reoxygenation.

Y Ueno1, K Shigenobu, S Nishio.   

Abstract

1. The present study was performed to determine whether beraprost, a new stable analogue of prostacyclin, may exert beneficial effects on the transmembrane action potentials during normoxia and hypoxia-reoxygenation in isolated right ventricular muscles of the guinea-pig. 2. Under normal oxygenation, beraprost (0.01-100 mumol-1) had no effects on the electrophysiological parameters. 3. Hypoxic conditions induced a decrease in action potential duration (APD) without affecting other action potential parameters. Beraprost inhibited this hypoxia-induced decrease in APD. However, beraprost had no effect on the decrease in contractile force induced by hypoxia, whereas it significantly improved the recovery of contractile force after reoxygenation. 4. Pinacidil-induced shortening of APD was not antagonized by beraprost. 5. Hypoxia significantly decreased the myocardial adenosine triphosphate (ATP) level, which was also prevented by beraprost. 6. These results suggested that beraprost may inhibit the hypoxia-induced shortening of APD by some mechanisms which contribute to the maintenance of muscle ATP level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8401913      PMCID: PMC2175748          DOI: 10.1111/j.1476-5381.1993.tb13722.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

Review 1.  Cardiac transmembrane potentials and metabolism.

Authors:  E Carmeliet
Journal:  Circ Res       Date:  1978-05       Impact factor: 17.367

2.  Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia.

Authors:  A M Lefer; M L Ogletree; J B Smith; M J Silver; K C Nicolaou; W E Barnette; G P Gasic
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

3.  PGI2 inhibits ischemia-induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator.

Authors:  K Schrör; K Addicks; H Darius; R Ohlendorf; P Rösen
Journal:  Thromb Res       Date:  1981 Jan 1-15       Impact factor: 3.944

4.  Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias.

Authors:  S J Coker; J R Parratt; I M Ledingham; I J Zeitlin
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart.

Authors:  H Araki; A M Lefer
Journal:  Circ Res       Date:  1980-11       Impact factor: 17.367

6.  Ionic currents during hypoxia in voltage-clamped cat ventricular muscle.

Authors:  A Vleugels; J Vereecke; E Carmeliet
Journal:  Circ Res       Date:  1980-10       Impact factor: 17.367

7.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation.

Authors:  S Bunting; R Gryglewski; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1976-12

8.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

9.  Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.

Authors:  B J Whittle; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1978-09

10.  Studies on the protective effect of prostacyclin in acute myocardial ischemia.

Authors:  M L Ogletree; A M Lefer; J B Smith; K C Nicolaou
Journal:  Eur J Pharmacol       Date:  1979-06       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.